News

ImaginAb, Inc. Appoints James D Marks, MD, PhD to Scientific Advisory Board

March 25, 2011

Inglewood, CA, March 25, 2011 -- ImaginAb, Inc. a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, announced today that Dr. James D. Marks, Professor of Anesthesia at the University of California, San Francisco (UCSF), has joined its Scientific Advisory Board (SAB). Dr. Marks is a world recognized pioneer in the field of antibody engineering, especially the use of antibody gene diversity libraries and display technologies to generate human therapeutic antibodies.

Dr. Marks received his undergraduate training at UC Berkeley, majoring in Biochemistry, and received his M.D. degree from UCSF in 1979.  He completed residencies in Internal Medicine and Anesthesia and a fellowship in Critical Care Medicine, all at UCSF.  He was a graduate student at the Medical Research Council Laboratory of Molecular Biology under the supervision of Dr. Greg Winter and received his Ph.D. in 1992 for a thesis titled "Making human antibody fragments in bacteria and bacteriophage." He currently directs a research group working on the production of medically relevant human antibodies using antibody gene diversity libraries and display technologies.  He has more than 180 relevant publications in the field and is an inventor on more than 100 issued or pending patents.

Dr. Marks also has extensive experience in the biotechnology industry.  He co-founded Hermes Biosciences, an early stage biotechnology company focused on the development of antibody targeted immunoliposomes for cancer therapy.  Hermes was acquired by Merrimack Pharmaceuticals in 2009.  Dr. Marks also serves on the SAB of Merrimack and Adimab and is a Director of Silver Creek Pharmaceuticals.

“We are extremely pleased to have Jim join our SAB.” noted ImaginAb’s Founder, Anna Wu Ph.D.  “His significant knowledge and experience in phage display technology for identification and production of human antibodies will be important as we look to advance our product candidates currently in development toward commercialization.”

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.